Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Ontarios Cancer Care Ontario coordinates screening for breast, cervical, and colorectal cancers
Do not exceed recommended serving
BPC-157 , ,
Retatrutide (development code LY3437943) is a 39-amino acid synthetic peptide developed by Eli Lilly as the first triple-receptor agonist targeting GLP-1R, GIPR, and GCGR in a single molecule
US$ 29.01
US$ 23.92
US$ 27.26
US$ 29.37
